The Food and Drug Administration and GlaxoSmithKline recently sent notice to healthcare professionals and pharmacists about a new black box warning on Dexedrine (dextroamphetamine sulfate). The drug, typically prescribed to treat Attention-Deficit Hyperactivity Disorder and narcolepsy, has been shown to cause sudden death in association with CNS stimulant treatment in children and adolescents with heart problems.
Sudden Death Associated with Dexedrine-New Black Box Warning Issued
The Food and Drug Administration and GlaxoSmithKline recently sent notice to healthcare professionals and pharmacists about a new black box warning on Dexedrine (dextroamphetamine sulfate). The drug, typically prescribed to treat Attention-Deficit Hyperactivity Disorder and narcolepsy, has been show
M. Brandon Smith
Brandon Smith is a partner at Childers, Schlueter & Smith (CSS) in Atlanta, Georgia. He represents individuals nationwide in pharmaceutical litigation, mass torts, product liability, and serious personal injury cases.
All articles
Tags:
Prescription Drugs
More in Prescription Drugs
See all
More from M. Brandon Smith
See all
